Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

OpGen

DB:6502
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6502
DB
$31M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • OpGen has significant price volatility in the past 3 months.
6502 Share Price and Events
7 Day Returns
-9.7%
DB:6502
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-79.5%
DB:6502
-7.4%
DE Biotechs
-14.2%
DE Market
6502 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
OpGen (6502) -9.7% 1.6% 71.1% -79.5% -99.6% -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 6502 underperformed the Biotechs industry which returned -7.4% over the past year.
  • 6502 underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
6502
Industry
5yr Volatility vs Market

Value

 Is OpGen undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for OpGen. This is due to cash flow or dividend data being unavailable. The share price is €1.95.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for OpGen's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are OpGen's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:6502 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-7.70
NasdaqCM:OPGN Share Price ** NasdaqCM (2020-04-08) in USD $2.21
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of OpGen.

DB:6502 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:OPGN Share Price ÷ EPS (both in USD)

= 2.21 ÷ -7.70

-0.29x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OpGen is loss making, we can't compare its value to the Europe Biotechs industry average.
  • OpGen is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does OpGen's expected growth come at a high price?
Raw Data
DB:6502 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.29x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
41.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for OpGen, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on OpGen's assets?
Raw Data
DB:6502 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.77
NasdaqCM:OPGN Share Price * NasdaqCM (2020-04-08) in USD $2.21
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:6502 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:OPGN Share Price ÷ Book Value per Share (both in USD)

= 2.21 ÷ 0.77

2.87x

* Primary Listing of OpGen.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OpGen is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess OpGen's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. OpGen has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is OpGen expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
41.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is OpGen expected to grow at an attractive rate?
  • Unable to compare OpGen's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare OpGen's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • OpGen's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:6502 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:6502 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 41.6%
DB:6502 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 69.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:6502 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:6502 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 15 -5 1
2020-12-31 5 -10 1
2020-04-09
DB:6502 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 3 -12 -12
2019-09-30 3 -11 -14
2019-06-30 3 -11 -13
2019-03-31 3 -12 -14
2018-12-31 3 -11 -13
2018-09-30 3 -11 -13
2018-06-30 3 -12 -13
2018-03-31 3 -12 -13
2017-12-31 3 -14 -15
2017-09-30 3 -16 -17
2017-06-30 3 -16 -19
2017-03-31 4 -18 -20

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • OpGen is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • OpGen's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:6502 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from OpGen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6502 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -0.37 -0.37 -0.37 1.00
2020-12-31 -0.99 -0.99 -0.99 1.00
2020-04-09
DB:6502 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -7.70
2019-09-30 -20.72
2019-06-30 -26.10
2019-03-31 -38.66
2018-12-31 -44.49
2018-09-30 -55.26
2018-06-30 -71.96
2018-03-31 -115.94
2017-12-31 -195.96
2017-09-30 -276.64
2017-06-30 -383.92
2017-03-31 -474.48

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if OpGen will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess OpGen's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
OpGen has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has OpGen performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare OpGen's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • OpGen does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare OpGen's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare OpGen's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
OpGen's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from OpGen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6502 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 3.50 -12.45 7.72
2019-09-30 3.44 -13.66 8.16
2019-06-30 3.34 -13.43 8.33
2019-03-31 3.12 -14.17 8.60
2018-12-31 2.95 -13.37 8.60
2018-09-30 3.18 -12.60 8.28
2018-06-30 3.37 -12.61 8.10
2018-03-31 3.29 -13.49 8.51
2017-12-31 3.21 -15.42 9.46
2017-09-30 3.23 -17.21 10.56
2017-06-30 3.24 -18.79 11.56
2017-03-31 3.72 -19.97 12.27
2016-12-31 4.03 -19.50 12.13
2016-09-30 4.35 -19.47 12.72
2016-06-30 4.57 -19.29 12.43
2016-03-31 3.76 -19.34 11.39
2015-12-31 3.16 -17.60 10.14
2015-09-30 2.95 -14.44 7.95 -3.08
2015-06-30 2.80 -11.56 6.21
2015-03-31 3.50 -7.75 4.95
2014-12-31 4.13 -6.30 4.37
2014-09-30 3.62 -8.83 4.39 3.08
2013-12-31 2.41 -15.51 5.82

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if OpGen has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if OpGen has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if OpGen improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess OpGen's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
OpGen has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is OpGen's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up OpGen's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • OpGen is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • OpGen's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of OpGen's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 9.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from OpGen Company Filings, last reported 3 months ago.

DB:6502 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 4.29 0.70 2.71
2019-09-30 -1.56 0.84 0.63
2019-06-30 1.83 0.84 3.06
2019-03-31 4.34 0.84 6.01
2018-12-31 3.31 1.06 4.57
2018-09-30 4.03 1.13 4.74
2018-06-30 6.40 1.30 7.43
2018-03-31 9.30 0.98 10.29
2017-12-31 1.40 1.01 1.85
2017-09-30 3.76 1.10 4.85
2017-06-30 -2.14 1.53 0.21
2017-03-31 0.55 1.00 1.67
2016-12-31 3.17 1.02 4.12
2016-09-30 3.28 1.10 4.26
2016-06-30 7.94 1.18 8.03
2016-03-31 3.25 0.99 3.97
2015-12-31 7.49 0.99 7.81
2015-09-30 11.94 1.00 11.19
2015-06-30 8.83 0.00 10.22
2015-03-31 -4.08 3.50 0.63
2014-12-31 -3.50 3.01 0.75
2014-09-30 -2.08 1.61 0.78
2013-12-31 0.17 0.01 1.40
  • OpGen's level of debt (16.4%) compared to net worth is satisfactory (less than 40%).
  • OpGen had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • OpGen has less than a year of cash runway based on current free cash flow.
  • OpGen has less than a year of cash runway if free cash flow continues to grow at historical rates of 5.8% each year.
X
Financial health checks
We assess OpGen's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. OpGen has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is OpGen's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from OpGen dividends. Estimated to be 0% next year.
If you bought €2,000 of OpGen shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate OpGen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate OpGen's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:6502 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:6502 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31 0.00 1.00
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as OpGen has not reported any payouts.
  • Unable to verify if OpGen's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of OpGen's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as OpGen has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of OpGen's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess OpGen's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can OpGen afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. OpGen has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of OpGen's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Oliver Schacht
AGE 48
TENURE AS CEO 0 years
CEO Bio

Dr. Oliver Schacht, Ph.D., has been the Member of Management Board and Managing Director at Curetis N.V. since April 2011 and served as its Chief Executive Officer until April 1, 2020. He serves as Director, President and Chief Executive Officer at OpGen, Inc. since April 1, 2020. He co-founded Epigenomics AG and also served as its Chief Financial Officer and Member of Executive Board until March 31, 2011. Dr. Schacht headed all central business functions at the Berlin headquarters including corporate finance, investor relations, PR, marketing & business development. He served as the Chief Financial Officer of Curetis N.V. Dr. Schacht served as the Chief Executive Officer of Epigenomics, Inc., of Epigenomics AG from January 1, 2006 to March 31, 2011 and also served as its Chief Financial Officer. He was an In-Charge of commercial operation in the US at Epigenomics. Dr. Schacht joined Mercer Management Consulting in 1995. As a Strategy Consultant, he completed projects (growth, restructuring, reengineering, mergers) in the automotive, chemical, service and machine tool manufacturing industries. He serves as a Director of Protagen AG. Dr. Schacht graduated in 1994 from the European School of Business (ESB Reutlingen) with a Diploma in European Business Administration, as well as has an Honors Degree (BA) from Middlesex University Business School in London. He completed a Master’s Course at the University of Cambridge, UK, specializing in M&A and Strategic Alliances. Dr. Schacht received his Ph.D. in Management Studies from the University of Cambridge (UK).

CEO Compensation
  • Insufficient data for Oliver to compare compensation growth.
  • Insufficient data for Oliver to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the OpGen management team in years:

5.5
Average Tenure
50
Average Age
  • The average tenure for the OpGen management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Tim Dec

TITLE
CFO & Corporate Secretary
COMPENSATION
$315K
AGE
60
TENURE
5 yrs

Vadim Sapiro

TITLE
Chief Information Officer
COMPENSATION
$311K
AGE
48
TENURE
8.3 yrs

Oliver Schacht

TITLE
CEO, President & Director
AGE
48

Johannes Bacher

TITLE
Chief Operating Officer
AGE
50

Michael Farmer

TITLE
Vice President of Marketing

Faranak Atrzadeh

TITLE
Chief Marketing & Scientific Affairs Officer

Terry Walker

TITLE
Senior Vice President of Research & Development
AGE
60
TENURE
5.5 yrs

Chris Emery

TITLE
Chief Commercial Officer for the Americas

Andreas Posch

TITLE
CEO of Ares Genetics GmbH
Board of Directors Tenure

Average tenure and age of the OpGen board of directors in years:

4.1
Average Tenure
64
Average Age
  • The tenure for the OpGen board of directors is about average.
Board of Directors

Bill Rhodes

TITLE
Independent Chairman
AGE
65

Oliver Schacht

TITLE
CEO, President & Director
AGE
48

Evan Jones

TITLE
Director
COMPENSATION
$448K
AGE
62

Don Elsey

TITLE
Independent Director
COMPENSATION
$49K
AGE
65
TENURE
1.2 yrs

Attila Lorincz

TITLE
Member of Clinical Advisory Board
AGE
64

James Snyder

TITLE
Member of Clinical Advisory Board

Debra Goff

TITLE
Member of Clinical Advisory Board
TENURE
4.1 yrs

Stefan Riedel

TITLE
Member of Clinical Advisory Board
TENURE
4.1 yrs

Morton Sommer

TITLE
Member of Clinical Advisory Board
TENURE
4.1 yrs

Trish Simner

TITLE
Member of Clinical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess OpGen's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. OpGen has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms (MRDOs). The company’s products include Acuitas AMR Gene Panel, an in vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance in urine specimens or bacterial colonies isolated from urine and other body sites; and QuickFISH and PNA FISH products, which are diagnostic tests for the identification of various infectious pathogens. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics offerings, which combine clinical lab test results with patient and hospital information, and provide analytics and insights to enable manage MDROs in the hospital and patient care environment. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.

Details
Name: OpGen, Inc.
6502
Exchange: DB
Founded: 2001
$28,367,969
13,958,444
Website: http://www.opgen.com
Address: OpGen, Inc.
708 Quince Orchard Road,
Suite 205,
Gaithersburg,
Maryland, 20878,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM OPGN Common Stock Nasdaq Capital Market US USD 05. May 2015
DB 6502 Common Stock Deutsche Boerse AG DE EUR 05. May 2015
Number of employees
Current staff
Staff numbers
39
OpGen employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 00:16
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/25
Last earnings filing: 2020/03/24
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.